Skip to main content

CORRECTION article

Front. Pharmacol., 11 January 2024
Sec. Inflammation Pharmacology
Volume 14 - 2023 | https://doi.org/10.3389/fphar.2023.1354581

Corrigendum: Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma

This article is a correction to:

  1. Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma

    1. Read original article
Can G. Leineweber,,Can G. Leineweber1,2,3Miriam Rabehl,Miriam Rabehl1,2Anne Pietzner,Anne Pietzner1,2Nadine Rohwer,,Nadine Rohwer1,2,4Michael RotheMichael Rothe5Maciej PechMaciej Pech6Bruno SangroBruno Sangro7Rohini SharmaRohini Sharma8Chris VerslypeChris Verslype9Bristi BasuBristi Basu10Christian SengelChristian Sengel11Jens RickeJens Ricke12Nils Helge SchebbNils Helge Schebb13Karsten-H. Weylandt, &#x;Karsten-H. Weylandt1,2*†Julia Benckert &#x;Julia Benckert14*†
  • 1Medical Department B, Division of Hepatology, Gastroenterology, Oncology, Hematology, Palliative Care, Endocrinology, and Diabetes, Brandenburg Medical School, University Hospital Ruppin-Brandenburg, Neuruppin, Germany
  • 2Faculty of Health Sciences, Joint Faculty of the Brandenburg University of Technology, Brandenburg Medical School and University of Potsdam, Potsdam, Germany
  • 3Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
  • 4Department of Molecular Toxicology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany
  • 5Lipidomix, Berlin, Germany
  • 6Department of Radiology and Nuclear Medicine, Otto-von-Guericke University, Magdeburg, Germany
  • 7Liver Unit and HPB Oncology Area, Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain
  • 8Department of Surgery and Cancer, Imperial College London, London, United Kingdom
  • 9Department of Digestive Oncology, University Hospitals Leuven, Leuven, Belgium
  • 10Department of Oncology, University of Cambridge, Cambridge, United Kingdom
  • 11Radiology Department, Grenoble University Hospital, La Tronche, France
  • 12Department of Radiology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany
  • 13Chair of Food Chemistry, Faculty of Mathematics and Natural Science, University of Wuppertal, Wuppertal, Germany
  • 14Department of Hepatology and Gastroenterology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt—Universität zu Berlin, Berlin, Germany

A Corrigendum on
Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma

by Leineweber CG, Rabehl M, Pietzner A, Rohwer N, Rothe M, Pech M, Sangro B, Sharma R, Verslype C, Basu B, Sengel C, Ricke J, Schebb NH, Weylandt K-H and Benckert J (2023). Front. Pharmacol. 14:1124214. doi: 10.3389/fphar.2023.1124214

In the published article, there was an error in Figures 2, 3, 5 as published. In an earlier version of the article, the asterisks in the figures mentioned above were not displayed as a visualization of the p-values. The corrected Figures and their unchanged captions appear below.

FIGURE 2
www.frontiersin.org

FIGURE 2. Effects on the concentrations of (A) AA-, (B) DHA-, and (C) EPA-derived epoxy-PUFA EETs, EDPs, and EEQs; and (D) AA-derived epoxy-PUFA plus dihydroxy-PUFA, (E) DHA-derived epoxy-PUFA plus dihydroxy-PUFA, and (F) EPA-derived epoxy-PUFA plus dihydroxy-PUFA in the plasma of n = 43 patients with hepatocellular carcinoma (HCC) without and undergoing sorafenib treatment (ng/mL ± standard error of the mean). Statistical differences were determined using the Wilcoxon signed-rank test (**p < 0.01; ***p < 0.001; ****p < 0.0001).

FIGURE 3
www.frontiersin.org

FIGURE 3. (A) Relative n-3 (docosahexaenoic acid, DHA; eicosapentaenoic acid, EPA) and n-6 (arachidonic acid, AA) PUFA levels in plasma from n = 43 patients with hepatocellular carcinoma (HCC) without and during sorafenib treatment individually, summarized and as a ratio. (B) Relative content of saturated fatty acids (SFA), monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA) in plasma from n = 43 patients with HCC without and undergoing sorafenib treatment. Statistical differences were determined using the Wilcoxon signed-rank test (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).

FIGURE 5
www.frontiersin.org

FIGURE 5. N-3 and n-6 PUFA-derived epoxides plus dihydroxy compounds as a marker for the presence of CYP metabolites in plasma from n = 43 patients with HCC without and undergoing sorafenib treatment. (A) Ratio of AA-derived products divided by AA plasma content, (B) ratio of DHA-derived products divided by DHA plasma content, (C) ratio of EPA-derived products divided by EPA plasma content (*p < 0.05, **p < 0.01; ***p < 0.001; ****p < 0.0001).

In the published article, there was an error in the Funding statement. The correct Funding statement appears below:

The author(s) declare financial support was received for publication of this article. Publication was funded by the Brandenburg Medical School (Medizinische Hochschule Brandenburg, MHB) publication fund supported by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) and by the Ministry of Science, Research and Culture of the State of Brandenburg.

In the published article, there was a typographical error. A correction has been made to the Introduction. The original sentence stated:

“These epoxymetabolites are then further metabolized via she into their biologically less active corresponding dihydroxy metabolites”

The corrected sentence appears below:

“These epoxymetabolites are then further metabolized via sEH into their biologically less active corresponding dihydroxy metabolites”

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: hepatocellular carcinoma, cytochrome P450, sorafenib, EET, EDP, omega-3 fatty acids, oxylipins, lipidomics

Citation: Leineweber CG, Rabehl M, Pietzner A, Rohwer N, Rothe M, Pech M, Sangro B, Sharma R, Verslype C, Basu B, Sengel C, Ricke J, Schebb NH, Weylandt K-H and Benckert J (2024) Corrigendum: Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma. Front. Pharmacol. 14:1354581. doi: 10.3389/fphar.2023.1354581

Received: 12 December 2023; Accepted: 13 December 2023;
Published: 11 January 2024.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2024 Leineweber, Rabehl, Pietzner, Rohwer, Rothe, Pech, Sangro, Sharma, Verslype, Basu, Sengel, Ricke, Schebb, Weylandt and Benckert. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Karsten-H. Weylandt, karsten.weylandt@mhb-fontane.de; Julia Benckert, julia.benckert@charite.de

†These authors have contributed equally to this work and share last authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.